title: Oral immunotherapy for the treatment of food allergy.
abstract: Oral immunotherapy (OIT) is an emerging new therapy for food allergy. With multiple small exploratory trials and some large randomized-controlled phase 2 trials recently published and under way, there is a clear progress and interest toward making this a treatment option for patients suffering from food allergies. However, there are still many questions to be answered and parameters to fine-tune before OIT becomes an accepted option outside of the research setting. This review covers the main milestones in the development of OIT for food allergy and further discusses important specific issues that will have direct impact on its clinical application. More specifically, previous publications showing evidence for the induction of tolerance are specifically reviewed and varying safety, tolerability and efficacy parameters from previous reports are also discussed.
authors.affiliation: a Stanford University; Stanford, CA USA.
authors.forename: Philippe
authors.initials: P
authors.lastname: Begin
authors.forename: R Sharon
authors.initials: RS
authors.lastname: Chinthrajah
authors.forename: Kari C
authors.initials: KC
authors.lastname: Nadeau
mesh_terms: D000284:Administration, Oral; D002986:Clinical Trials as Topic; D005512:Food Hypersensitivity / Q000628:therapy*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D007167:Immunotherapy / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D007155:Immunologic Factors
keywords: Food allergy; Oral immunotherapy (OIT); efficacy; omalizumab; rush; safety; tolerance